Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01319331 · ClinicalTrials.gov registry record · Phase 1
The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01319331: Completed Phase 1 study, sponsored by University of Colorado, Denver.
NCT01319331 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01319331, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the drug Alpha-1 Antitrypsin (AAT, Aralast NP) will preserve beta-cell function and help slow the progression of type 1 diabetes.
Interventions
- DRUG Alpha 1-Antitrypsin (AAT, Aralast NP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-10 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
What the finished NCT01319331 record still lists
NCT01319331 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which Alpha 1-Antitrypsin (AAT, Aralast NP) is the first listed.
NCT01319331 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01319331 about?
NCT01319331 is a clinical study titled "The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes". The purpose of this study is to determine if the drug Alpha-1 Antitrypsin (AAT, Aralast NP) will preserve beta-cell function and help slow the progression of type 1 diabetes.
What is the current status of trial NCT01319331?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-10. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01319331?
The interventions under investigation include: Alpha 1-Antitrypsin (AAT, Aralast NP) (DRUG).
Who is sponsoring clinical trial NCT01319331?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01319331's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia